Mifepristone promotes adiponectin production and improves insulin sensitivity in a mouse model of diet-induced-obesity

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Hashimoto, Takeshi ^a   Igarashi, Junsuke ^a   Hasan, Arif U ^a   Ohmori, Koji ^a   Kohno, Masakazu ^a   Nagai, Yukiko ^a   Yamashita, Tetsuo ^a   Kosaka, Hiroaki ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; MESSENGER RNA; MIFEPRISTONE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL SIZE; CONTROLLED STUDY; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER INJURY; MALE; MOUSE; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; UPREGULATION;

3T3-L1 CELLS; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; CELL DIFFERENTIATION; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; INSULIN RESISTANCE; MALE; MICE; MIFEPRISTONE; OBESITY;

EID: 84892377630     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079724     Document Type: Article

References (46)

1. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121(6): 2111-2117. doi:10.1172/JCI57132. PubMed: 21633179.
2. Seino S, Shibasaki T, Minami K (2011) Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest 121(6): 2118-2125. doi:10.1172/JCI45680. PubMed: 21633180.
3. Sharma AM (2006) The obese patient with diabetes mellitus: from research targets to treatment options. Am J Med 119 Suppl 1)(5: S17-S23. doi:10.1016/j.amjmed.2005.10.044. PubMed: 16563943.
4. O'Rahilly S, Barroso I, Wareham NJ (2005) Genetic factors in type 2 diabetes: the end of the beginning? Science 307(5708): 370-373. doi: 10.1126/science.1104346. PubMed: 15662000.
5. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulangé A et al. (2006) Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 49(9): 2162-2173. doi:10.1007/s00125-006-0335-z. PubMed: 16865359.
6. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G (2003) Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52(7): 1779-1785. doi:10.2337/diabetes.52.7.1779. PubMed: 12829646.
7. Berg AH, Combs TP, Scherer PE (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13(2): 84-89. doi:10.1016/S1043-2760(01)00524-0. PubMed: 11854024.
8. Schreiber JR, Hsueh AJ, Baulieu EE (1983) Binding of the anti-progestin RU-486 to rat ovary steroid receptors. Contraception 28(1): 77-85. doi:10.1016/S0010-7824(83)80008-0. PubMed: 6627946.
9. Cadepond F, Ulmann A, Baulieu EE (1997) RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 48: 129-156. doi:10.1146/annurev.med. 48.1.129. PubMed: 9046951.
10. Taylor AI, Frizzell N, McKillop AM, Flatt PR, Gault VA (2009) Effect of RU486 on hepatic and adipocyte gene expression improves diabetes control in obesity-type 2 diabetes. Horm Metab Res 41(12): 899-904. doi:10.1055/s-0029- 1234071. PubMed: 19670152.
11. Wang Y, Nakagawa Y, Liu L, Wang W, Ren X et al. (2011) Tissuespecific dysregulation of hexose-6-phosphate dehydrogenase and glucose-6-phosphate transporter production in db/db mice as a model of type 2 diabetes. Diabetologia 54(2): 440-450. doi:10.1007/s00125-010-1956-9. PubMed: 21052977.
12. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH et al. (2005) Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 28(11): 1263-1269. doi:10.1007/BF02978210. PubMed: 16350853.
13. Kusunoki M, Cooney GJ, Hara T, Storlien LH (1995) Amelioration of high-fat feeding-induced insulin resistance in skeletal muscle with the antiglucocorticoid RU486. Diabetes 44(6): 718-720. doi:10.2337/diabetes.44.6. 718. PubMed: 7789638.
14. Hashimoto T, Igarashi J, Kosaka H (2009) Sphingosine kinase is induced in mouse 3T3-L1 cells and promotes adipogenesis. J Lipid Res 50(4): 602-610. PubMed: 19020339.
15. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50(9): 2094-2099. doi:10.2337/diabetes.50. 9.2094. PubMed: 11522676.
16. Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K et al. (2007) Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50(4): 750-755. doi:10.1161/HYPERTENSIONAHA. 107.093955. PubMed: 17646573.
17. Liao W, Nguyen MT, Yoshizaki T, Favelyukis S, Patsouris D et al. (2007) Suppression of PPAR-gamma attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 293(1): E219-E227. doi: 10.1152/ajpendo.00695.2006. PubMed: 17389706.
18. Liao W, Nguyen MT, Imamura T, Singer O, Verma IM et al. (2006) Lentiviral short hairpin ribonucleic acid-mediated knockdown of GLUT4 in 3T3-L1 adipocytes. Endocrinology 147(5): 2245-2252. doi: 10.1210/en.2005-1638. PubMed: 16497797.
19. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T et al. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279(13): 12152-12162. PubMed: 14699128.
20. Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K et al. (2003) Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 228(10): 1111-1117. PubMed: 14610248.
21. Lee YM, Choi JS, Kim MH, Jung MH, Lee YS et al. (2006) Effects of dietary genistein on hepatic lipid metabolism and mitochondrial function in mice fed high-fat diets. Nutrition 22(9): 956-964. doi:10.1016/j.nut. 2005.12.014. PubMed: 16814985.
22. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS et al. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112(1): 91-100. doi:10.1172/JCI17797. PubMed: 12840063.
23. Yang B, Trump RP, Shen Y, McNulty JA, Clifton LG et al. (2008) RU486 did not exacerbate cytokine release in mice challenged with LPS nor in db/db mice. BMC Pharmacol 8: 7. doi:10.1186/1471-2210-8-S1-A7. PubMed: 18474108.
24. Gross C, Blasey CM, Roe RL, Allen K, Block TS et al. (2009) Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther 26(10): 959-969. doi:10.1007/s12325-009-0070-1. PubMed: 19888560.
25. Gross C, Blasey CM, Roe RL, Belanoff JK (2010) Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring) 18(12): 2295-2300. doi:10.1038/oby.2010.51. PubMed: 20339369.
26. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423(6941): 762-769. doi:10.1038/nature01705. PubMed: 12802337.
27. Evans RM, Barish GD, Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10(4): 355-361. doi:10.1038/nm1025. PubMed: 15057233.
28. Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N et al. (2011) Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 13(4): 401-412. doi:10.1016/j.cmet.2011.02.010. PubMed: 21459325.
29. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR (2005) PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 288(6): E1195-E1205. doi:10.1152/ajpendo.00513.2004. PubMed: 15644454.
30. White MF (1997) The insulin signalling system and the IRS proteins. Diabetologia 40 Suppl 2: S2-17. doi:10.1007/s001250051387. PubMed: 9248696.
31. Hosoe T, Nakahama T, Inouye Y (2005) Divergent Modes of Induction of Rat Hepatic and Pulmonary CYP3A1 by Dexamethasone and Pregnenolone 16α-Carbonitrile. J Health Sci 51(1): 75-79. doi:10.1248/jhs.51.75.
32. Saccò M, Valenti G, Corvi Mora P, Wu FC, Ray DW (2002) DHEA, a selective glucocorticoid receptor antagonist: its role in immune system regulation and metabolism. J Endocrinol Invest 25(10 Suppl): 81-82. PubMed: 12508928.
33. Lähteenmäki P, Ylöstalo P, Sipinen S, Toivonen J, Ruusuvaara L et al. (1980) Return of ovulation after abortion and after discontinuation of oral contraceptives. Fertil Steril 34(3): 246-249. PubMed: 7409246.
34. Feldman D, Couropmitree C (1976) Intrinsic mineralocorticoid agonist activity of some nonsteroidal anti-inflammatory drugs. A postulated mechanism for sodium retention. J Clin Invest 57(1): 1-7. doi:10.1172/JCI108249. PubMed: 173739.
35. Lin S, Han Y, Shi Y, Rong H, Zheng S et al. (2012) Revealing a steroid receptor ligand as a unique PPARgamma agonist. Cell Res 22(4): 746-756. doi:10.1038/cr.2011.162. PubMed: 21986665.
36. Moriuchi A, Yamasaki H, Shimamura M, Kita A, Kuwahara H et al. (2007) Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPARgamma activation. Biochem Biophys Res Commun 356(4): 1024-1030. doi:10.1016/j.bbrc.2007.03.084. PubMed: 17399685.
37. Lowe CE, O'Rahilly S, Rochford JJ (2011) Adipogenesis at a glance. J Cell Sci 124(16): 2681-2686. doi:10.1242/jcs.079699.
38. Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ et al. (2009) Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab 296(3): E480-E489. PubMed: 19088251.
39. Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y et al. (2007) Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132(1): 282-293. doi:10.1053/j.gastro. 2006.10.014. PubMed: 17241878.
40. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R et al. (2003) Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52(6): 1355-1363. doi:10.2337/diabetes. 52.6.1355. PubMed: 12765944.
41. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y et al. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101(6): 1354-1361. doi:10.1172/JCI1235. PubMed: 9502777.
42. Hasan AU, Ohmori K, Hashimoto T, Kamitori K, Hirata Y et al. (2011) Pioglitazone promotes preadipocyte proliferation by downregulating p16(Ink4a). Biochem Biophys Res Commun 411(2): 375-380. doi: 10.1016/j.bbrc.2011.06.152. PubMed: 21741366.
43. Saltiel AR, Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45(12): 1661-1669. doi:10.2337/diab.45.12.1661. PubMed: 8922349.
44. Musgrove EA, Lee CS, Cornish AL, Swarbrick A, Sutherland RL (1997) Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 11(1): 54-66. doi:10.1210/me.11.1.54. PubMed: 8994188.
45. Blanquicett C, Roman J, Hart CM (2008) Thiazolidinediones as anticancer agents. Cancer Ther 6: 25-34(A):25-34 PubMed: 19079765.
46. Wang Y, Lu G, Wong WP, Vliegenthart JF, Gerwig GJ et al. (2004) Proteomic and functional characterization of endogenous adiponectin purified from fetal bovine serum. Proteomics 4(12): 3933-3942. doi: 10.1002/pmic.200400826. PubMed: 15378692.